Commodore Capital LP Raises Stock Position in Soleno Therapeutics, Inc. $SLNO

Commodore Capital LP raised its holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 121.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,350,000 shares of the company’s stock after acquiring an additional 740,000 shares during the quarter. Soleno Therapeutics comprises approximately 4.5% of Commodore Capital LP’s holdings, making the stock its 8th largest position. Commodore Capital LP owned about 2.51% of Soleno Therapeutics worth $91,260,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of SLNO. Vanguard Group Inc. lifted its stake in shares of Soleno Therapeutics by 12.8% in the 3rd quarter. Vanguard Group Inc. now owns 2,807,149 shares of the company’s stock valued at $189,763,000 after purchasing an additional 319,317 shares during the last quarter. Avoro Capital Advisors LLC increased its position in Soleno Therapeutics by 25.7% during the third quarter. Avoro Capital Advisors LLC now owns 2,577,777 shares of the company’s stock worth $174,258,000 after buying an additional 527,777 shares during the last quarter. Wellington Management Group LLP raised its holdings in Soleno Therapeutics by 272.3% during the third quarter. Wellington Management Group LLP now owns 2,312,095 shares of the company’s stock valued at $156,298,000 after buying an additional 1,691,057 shares in the last quarter. Invesco Ltd. raised its holdings in Soleno Therapeutics by 132.3% during the third quarter. Invesco Ltd. now owns 1,500,525 shares of the company’s stock valued at $101,435,000 after buying an additional 854,551 shares in the last quarter. Finally, Westfield Capital Management Co. LP lifted its position in shares of Soleno Therapeutics by 18.0% in the second quarter. Westfield Capital Management Co. LP now owns 1,429,756 shares of the company’s stock worth $119,785,000 after buying an additional 218,511 shares during the last quarter. Institutional investors own 97.42% of the company’s stock.

Soleno Therapeutics Trading Down 8.1%

Soleno Therapeutics stock opened at $33.76 on Friday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 5.55 and a current ratio of 5.80. The business’s 50-day simple moving average is $40.74 and its 200-day simple moving average is $51.05. The firm has a market capitalization of $1.74 billion, a PE ratio of 146.79 and a beta of -3.16. Soleno Therapeutics, Inc. has a 52 week low of $32.63 and a 52 week high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.16. The business had revenue of $91.73 million for the quarter, compared to analyst estimates of $88.55 million. Equities research analysts forecast that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on SLNO. Wall Street Zen upgraded Soleno Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday. Wells Fargo & Company reduced their target price on Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating for the company in a report on Friday, February 27th. Robert W. Baird set a $107.00 target price on Soleno Therapeutics in a research report on Tuesday, January 13th. TD Cowen lowered their price target on Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Finally, Wolfe Research set a $60.00 price target on shares of Soleno Therapeutics in a research report on Monday, January 12th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $106.85.

Key Headlines Impacting Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Recent operational data: Soleno reported quarterly results on Feb. 25 that beat consensus — $0.80 EPS vs. $0.64 estimate and revenue roughly $91.7M vs. ~$88.6M — a near‑term fundamental positive that may temper downside if litigation risk abates.
• Negative Sentiment: Class action filings allege Soleno misled investors about the integrity, safety and results of its DCCR Phase 3 program, citing the company’s Nov. 5, 2025 disclosures; the Hagens Berman notice is a representative filing. Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions — Hagens Berman
• Negative Sentiment: Multiple national plaintiff firms (Robbins Geller, Schall, Kessler Topaz, Rosen, Glancy Prongay, Levi & Korsinsky, etc.) are actively soliciting clients and reminding investors of the May 5, 2026 lead‑plaintiff deadline, increasing the likelihood of consolidated litigation and potential settlement exposure. Deadline Approaching: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
• Negative Sentiment: Allegations across notices include claims of concealed safety issues, material misstatements/omissions about trial conduct and efficacy, and even charges of “sham” trials — outcomes that, if substantiated, could lead to regulatory inquiry, management distraction, legal costs and damages payments.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.